Cytarabine
- PDF / 172,051 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 8 Downloads / 153 Views
S
Pancytopenia: 3 case reports In a case report, three neonates [2 girls and 1 boy; exact ages not stated] were described, who developed pancytopenia during treatment with cytarabine for Down syndrometransient abnormal myelopoiesis [DS-TAM; routes, time to reaction onsets and outcomes not stated]. Case 1: The mother of the girl underwent an antenatal ultrasound examination at 38 weeks of gestation, during which the girl was diagnosed with hydrops fetalis (HF). Consequently, the mother underwent a caesarean section on the same day, and the girl was delivered. Immediately after birth, she (the girl) was intubated. Examinations led to the diagnosis of trisomy-21, persistent pulmonary hypertension of the newborn and hyperuricaemia. Therefore, her treatment was started with nitric oxide, unspecified catecholamine and hydrocortisone. Additionally, on day 2 and day 3, she underwent exchange transfusion process, which was followed by the initiation of low dose cytarabine 0.9 mg/kg/day on day 3. Subsequent improvement was noted in her condition. However, she developed cytarabine therapy related pancytopenia. Hence, on day 8, the cytarabine therapy was discontinued. Due to pancytopenia, she received a blood transfusion on day 26, along with unspecified granulocytecolony stimulating factors. On day 48, she was discharged. At the time of last follow up examination (at the age of 3 years), no signs of distinct liver dysfunction or acute myeloid leukaemia (symptoms of underlying condition) were noted. Case 2: A girl was delivered at 38 weeks by caesarean section due to hydrops and ventricular septal defects (VSD). After birth, she was intubated. Examinations led to the diagnosis of trisomy-21 and persistent pulmonary hypertension of the newborn. Her treatment was started with nitric oxide, epoprostenol [prostaglandin i2], unspecified catecholamine and hydrocortisone. On day 1 and day 2, she underwent exchange transfusion process. On day 3, low dose cytarabine 0.9 mg/kg per day was started due to the persistence of disseminated intravascular coagulation. Cytarabine therapy was continued for 7 days. gradual improvement was noted in her respiratory status and circulatory failure. However, she developed cytarabine therapy related pancytopenia. She received blood transfusion and treatment with unspecified granulocyte-colony stimulating factors due to the pancytopenia. At the age of 4 months, she was discharged after the symptoms of her underlying condition normalised. At the time of last follow up examination (at the age of 2 years and 9 months), no signs of distinct liver dysfunction or acute myeloid leukaemia (symptoms of underlying condition) were noted. Case 3: A boy was delivered by caesarean section at 33 weeks due to the diagnosis of cardiomegaly, fetal hepatosplenomegaly and fetal pericardial effusion. Immediately after birth, he was intubated. After birth, he was diagnosed with trisomy-21 and persistent pulmonary hypertension of the newborn. His treatment was started with nitric oxide, unspecified catecholamine and hydrocor
Data Loading...
